Neurocrine Biosciences, Inc. (NBIX)
153.04
+0.47
(+0.31%)
USD |
NASDAQ |
Aug 24, 16:00
153.04
0.00 (0.00%)
After-Hours: 18:24
Neurocrine Biosciences Debt to Equity Ratio : 0.1088 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.1088 |
| March 31, 2026 | 0.1192 |
| December 31, 2025 | 0.1449 |
| September 30, 2025 | 0.1597 |
| June 30, 2025 | 0.1818 |
| March 31, 2025 | 0.1945 |
| December 31, 2024 | 0.1914 |
| September 30, 2024 | 0.1053 |
| June 30, 2024 | 0.1162 |
| March 31, 2024 | 0.2292 |
| December 31, 2023 | 0.2063 |
| September 30, 2023 | 0.1367 |
| June 30, 2023 | 0.1492 |
| March 31, 2023 | 0.1652 |
| December 31, 2022 | 0.1641 |
| September 30, 2022 | 0.1833 |
| June 30, 2022 | 0.2007 |
| March 31, 2022 | 0.3573 |
| December 31, 2021 | 0.3325 |
| September 30, 2021 | 0.3363 |
| June 30, 2021 | 0.352 |
| March 31, 2021 | 0.3664 |
| December 31, 2020 | 0.3752 |
| September 30, 2020 | 0.6437 |
| June 30, 2020 | 0.6172 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.7261 |
| December 31, 2019 | 0.7911 |
| September 30, 2019 | 0.8463 |
| June 30, 2019 | 0.9684 |
| March 31, 2019 | 1.133 |
| December 31, 2018 | 0.8081 |
| September 30, 2018 | 0.8573 |
| June 30, 2018 | 1.004 |
| March 31, 2018 | 1.027 |
| December 31, 2017 | 0.9932 |
| September 30, 2017 | 1.051 |
| June 30, 2017 | 1.045 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Amarin Corp. Plc | 0.0118 |
| Liquidia Corp. | 0.9374 |
| Incyte Corp. | 0.006 |
| Krystal Biotech, Inc. | 0.0065 |
| Halozyme Therapeutics, Inc. | 14.95 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 5.359B |
| Total Liabilities (Quarterly) | 1.666B |
| Shareholders Equity (Quarterly) | 3.694B |
| Current Ratio | 1.872 |
| Net Debt Paydown Yield | 0.11% |